$MLAB
MESA LABORATORIES INC /CO/ Stock $mlab

$mlab Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000143774921018622 Filed on August 05, 2021

Income Statement

Concept	2021 Q2	2020 Q2
Revenue	$34.92M	$29.94M
YoY Change	16.63%	13.9%
Cost Of Revenue	$12.71M	$9.601M
YoY Change	32.37%	-5.4%
Gross Profit	$22.21M	$20.34M
YoY Change	9.2%	25.52%
Gross Profit Margin	63.61%	67.93%
Selling, General & Admin	$16.28M	$14.17M
YoY Change	14.84%	45.7%
% of Gross Profit	73.28%	69.69%
Research & Development	$2.811M	$2.596M
YoY Change	8.28%	154.76%
% of Gross Profit	12.66%	12.76%
Depreciation & Amortization	$4.572M	$3.908M
YoY Change	16.99%	79.18%
% of Gross Profit	20.58%	19.21%
Operating Expenses	$19.09M	$16.77M
YoY Change	13.82%	56.04%
Operating Profit	$3.123M	$3.570M
YoY Change	-12.52%	-33.79%
Interest Expense	$874.0K	$1.919M
YoY Change	-54.46%	385.82%
% of Operating Profit	27.99%	53.75%
Other Income/Expense, Net	-$1.705M	-$2.816M
YoY Change	-39.45%	8700.0%
Pretax Income	$1.418M	$754.0K
YoY Change	88.06%	-85.93%
Income Tax	-$577.0K	-$463.0K
% Of Pretax Income	-40.69%	-61.41%
Net Earnings	$1.995M	$1.217M
YoY Change	63.93%	-73.88%
Net Earnings / Revenue	5.71%	4.06%
Basic Earnings Per Share	$0.39	$0.27
Diluted Earnings Per Share	$0.38	$0.26
COMMON SHARES
Basic Shares Outstanding	5.152M	4.528M
Diluted Shares Outstanding	5.301M	4.669M

Balance Sheet

Concept	2021 Q2	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$275.7M	$231.0M
YoY Change	19.35%	3064.38%
Cash & Equivalents	$275.7M	$231.0M
Short-Term Investments
Other Short-Term Assets	$6.901M	$8.000M
YoY Change	-13.74%	21.21%
Inventory	$24.61M	$12.90M
Prepaid Expenses
Receivables	$20.58M	$17.93M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$315.3M	$269.8M
YoY Change	16.89%	697.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$21.95M	$21.80M
YoY Change	0.71%	-0.85%
Goodwill	$162.7M	$153.9M
YoY Change	5.7%	128.33%
Intangibles	$109.7M	$117.5M
YoY Change	-6.68%	248.18%
Long-Term Investments
YoY Change
Other Assets	$2.200M	$2.254M
YoY Change	-2.4%	65.61%
Total Long-Term Assets	$297.2M	$307.0M
YoY Change	-3.19%	143.93%
TOTAL ASSETS
Total Short-Term Assets	$315.3M	$269.8M
Total Long-Term Assets	$297.2M	$307.0M
Total Assets	$612.5M	$576.7M
YoY Change	6.2%	261.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.045M	$2.812M
YoY Change	43.85%	-10.16%
Accrued Expenses	$9.922M	$5.944M
YoY Change	66.92%	24.04%
Deferred Revenue	$8.941M	$5.858M
YoY Change	52.63%	43.37%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$33.45M	$20.48M
YoY Change	63.36%	-3.98%
LONG-TERM LIABILITIES
Long-Term Debt	$168.7M	$141.6M
YoY Change	19.13%	708.59%
Other Long-Term Liabilities	$530.0K	$1.190M
YoY Change	-55.46%	70.98%
Total Long-Term Liabilities	$530.0K	$1.190M
YoY Change	-55.46%	-93.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$33.45M	$20.48M
Total Long-Term Liabilities	$530.0K	$1.190M
Total Liabilities	$213.5M	$194.5M
YoY Change	9.76%	378.78%
SHAREHOLDERS EQUITY
Retained Earnings	$79.31M	$72.24M
YoY Change	9.79%	-6.51%
Common Stock	$298.2M	$306.9M
YoY Change	-2.83%	607.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$399.0M	$382.2M
YoY Change
Total Liabilities & Shareholders Equity	$612.5M	$576.7M
YoY Change	6.2%	261.2%

Cashflow Statement

Concept	2021 Q2	2020 Q2
OPERATING ACTIVITIES
Net Income	$1.995M	$1.217M
YoY Change	63.93%	-73.88%
Depreciation, Depletion And Amortization	$4.572M	$3.908M
YoY Change	16.99%	79.18%
Cash From Operating Activities	$9.589M	$2.260M
YoY Change	324.29%	212.15%
INVESTING ACTIVITIES
Capital Expenditures	$653.0K	$216.0K
YoY Change	202.31%	-4.42%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$653.0K	-$216.0K
YoY Change	202.31%	-92.23%
FINANCING ACTIVITIES
Cash Dividend Paid	$824.0K	$704.0K
YoY Change	17.05%	12.82%
Common Stock Issuance & Retirement, Net	$0.00	$145.9M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$265.0K	$146.9M
YoY Change	-99.82%	-16153.01%
NET CHANGE
Cash From Operating Activities	$9.589M	$2.260M
Cash From Investing Activities	-$653.0K	-$216.0K
Cash From Financing Activities	$265.0K	$146.9M
Net Change In Cash	$11.85M	$149.6M
YoY Change	-92.08%	-5311.53%
FREE CASH FLOW
Cash From Operating Activities	$9.589M	$2.260M
Capital Expenditures	$653.0K	$216.0K
Free Cash Flow	$8.936M	$2.044M
YoY Change	337.18%	310.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5198892
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5198892
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23787000	USD
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5140568
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20578000	USD
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5203412
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	232000	USD
CY2021Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	218000	USD
CY2021Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2021Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5140568
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	9315000	USD
CY2020Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.16
CY2021Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
CY2021Q1	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
CY2021Q1	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	230822000	USD
CY2021Q2	us-gaap	Income Tax Examination Year Under Examination IncomeTaxExaminationYearUnderExamination	2019
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	275710000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	263865000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	12122000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	11178000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6901000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4919000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	315311000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	303749000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21951000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21998000	USD
CY2021Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	623000	USD
CY2021Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	616000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2200000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2530000	USD
CY2021Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	109680000	USD
CY2021Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	111741000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	162725000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	160841000	USD
CY2021Q2	us-gaap	Assets Assets	612490000	USD
CY2021Q1	us-gaap	Assets Assets	601475000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4045000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4473000	USD
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10540000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9388000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8941000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8777000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9922000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9945000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	213487000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	3570000	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	874000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	1919000	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-831000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-897000	USD
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1705000	USD
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2816000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1418000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	754000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-577000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	33448000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	32583000	USD
CY2021Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	10814000	USD
CY2021Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	16275000	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	530000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	715000	USD
CY2021Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	168695000	USD
CY2021Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	145675000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	195248000	USD
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	298203000	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	317652000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	79313000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	72459000	USD
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	21487000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	16116000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	399003000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	406227000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	612490000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	601475000	USD
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	12709000	USD
CY2020Q2	us-gaap	Cost Of Revenue CostOfRevenue	9601000	USD
CY2021Q2	us-gaap	Gross Profit GrossProfit	22211000	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	20340000	USD
CY2021Q2	us-gaap	Selling Expense SellingExpense	4858000	USD
CY2020Q2	us-gaap	Selling Expense SellingExpense	4075000	USD
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11419000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10099000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2811000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2596000	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	19088000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	16770000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	3123000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-463000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	1995000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	1217000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.39
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.38
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.26
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5152000
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4528000
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5301000
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4669000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	1995000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	1217000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	5371000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	12860000	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	7366000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	14077000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	1995000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	1217000	USD
CY2021Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4572000	USD
CY2020Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3908000	USD
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	2197000	USD
CY2020Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1268000	USD
CY2021Q2	us-gaap	Paid In Kind Interest PaidInKindInterest	221000	USD
CY2020Q2	us-gaap	Paid In Kind Interest PaidInKindInterest	1326000	USD
CY2021Q2	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	826000	USD
CY2020Q2	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-55000	USD
CY2021Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3285000	USD
CY2020Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4251000	USD
CY2021Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	753000	USD
CY2020Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1194000	USD
CY2021Q2	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1631000	USD
CY2020Q2	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1982000	USD
CY2021Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-476000	USD
CY2020Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-913000	USD
CY2021Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	867000	USD
CY2020Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4377000	USD
CY2021Q2	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	138000	USD
CY2020Q2	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1299000	USD
CY2021Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	9589000	USD
CY2020Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2260000	USD
CY2021Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	653000	USD
CY2020Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	216000	USD
CY2021Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-653000	USD
CY2020Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-216000	USD
CY2021Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	145935000	USD
CY2021Q2	us-gaap	Payments Of Dividends PaymentsOfDividends	824000	USD
CY2020Q2	us-gaap	Payments Of Dividends PaymentsOfDividends	704000	USD
CY2021Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1089000	USD
CY2020Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1654000	USD
CY2021Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	265000	USD
CY2020Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	146885000	USD
CY2021Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2644000	USD
CY2020Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	642000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11845000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	149571000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	263865000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	81380000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	275710000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	230951000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	406227000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1089000	USD
CY2021Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	824000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2197000	USD
CY2021Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	19000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	96.18
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	5371000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	1995000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	399003000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	220013000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	145935000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1654000	USD
CY2020Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	704000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1268000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	12860000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	1217000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	382234000	USD
CY2021Q2	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	4	pure
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34920000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29941000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34920000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29941000	USD
CY2021Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	8994000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2448000	USD
CY2021Q2	mlab	Contract With Customer Liability Increase During Period Net Of Revenue Recognized ContractWithCustomerLiabilityIncreaseDuringPeriodNetOfRevenueRecognized	3144000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	11338000	USD
CY2021Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	9690000	USD
CY2021Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	230822000	USD
CY2021Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	6375000	USD
CY2020Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	5755000	USD
CY2021Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	447000	USD
CY2020Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	426000	USD
CY2021Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5300000	USD
CY2020Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4997000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	12122000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	11178000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	178945000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	69265000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	109680000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	176866000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	65125000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	111741000	USD
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3816000	USD
CY2020Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3354000	USD
CY2020Q2	us-gaap	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Intangibles BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles	-334000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	28856000	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2021Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	2000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	170.93
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	14920000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	14405000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	12808000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	12017000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	160841000	USD
CY2021Q2	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	1884000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	162725000	USD
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2197000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1268000	USD
CY2021Q2	mlab	Employee Service Sharebased Compensation Tax Expense Benefit From Compensation Expense EmployeeServiceSharebasedCompensationTaxExpenseBenefitFromCompensationExpense	-2785000	USD
CY2020Q2	mlab	Employee Service Sharebased Compensation Tax Expense Benefit From Compensation Expense EmployeeServiceSharebasedCompensationTaxExpenseBenefitFromCompensationExpense	-925000	USD
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	-588000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	343000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	253000
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	129.55
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y8M12D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	232000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	131.90
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y6M
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	32299000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	1995000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	1217000	USD
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5152000
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4528000
CY2021Q2	mlab	Incremental Common Shares Attributable To Dilutive Effect Of Stock Options IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptions	108000
CY2020Q2	mlab	Incremental Common Shares Attributable To Dilutive Effect Of Stock Options IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptions	130000
CY2021Q2	us-gaap	Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends	41000
CY2020Q2	us-gaap	Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends	11000
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5301000
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4669000
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.39
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.38
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.26
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	654000
CY2020Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	661000
CY2021Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.407	pure
CY2020Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.614	pure
CY2021Q2	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021Q2	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	pure
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34920000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29941000	USD
CY2021Q2	us-gaap	Gross Profit GrossProfit	22211000	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	20340000	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	19088000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	16770000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	3123000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	3570000	USD
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1705000	USD
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2816000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1418000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	754000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	12122000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	11178000	USD

Files In Submission

Name	View Source	Status
0001437749-21-018622-index-headers.html	Edgar Link	pending
0001437749-21-018622-index.html	Edgar Link	pending
0001437749-21-018622.txt	Edgar Link	pending
0001437749-21-018622-xbrl.zip	Edgar Link	pending
ex_256046.htm	Edgar Link	pending
ex_256047.htm	Edgar Link	pending
ex_256048.htm	Edgar Link	pending
ex_256049.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mlab-20210630.xsd	Edgar Link	pending
mlab-20210630_cal.xml	Edgar Link	unprocessable
mlab-20210630_def.xml	Edgar Link	unprocessable
mlab-20210630_lab.xml	Edgar Link	unprocessable
mlab-20210630_pre.xml	Edgar Link	unprocessable
mlab20210630_10q.htm	Edgar Link	pending
mlab20210630_10q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MLAB
MESA LABORATORIES INC /CO/ Stock $mlab

2021 Q2 Form 10-Q Financial Statement

#000143774921018622 Filed on August 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MLAB MESA LABORATORIES INC /CO/ Stock $mlab

2021 Q2 Form 10-Q Financial Statement

#000143774921018622 Filed on August 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MLAB
MESA LABORATORIES INC /CO/ Stock $mlab